logo-loader
NASDAQ:REGN

Regeneron Pharmaceuticals

Receive alerts
Market:
NASDAQ
Market Cap:
$44.35 billion
Price
403.15 USD
Change
1.00%
52 weeks high
442.00
52 weeks low
271.37

In brief

Regeneron Pharmaceuticals, Inc. (Regeneron) is engaged in the research, development and commercialization of therapeutics to treat human disorders and conditions. The Company’s facilities are primarily located in New York. Its late stage programs are rilonacept, which is being developed for the prevention and treatment of gout-related flares; VEGF Trap-Eye, which is being developed in eye diseases using intraocular delivery in collaboration with Bayer HealthCare LLC, and aflibercept (VEGF Trap), which is being developed in oncology in collaboration with the sanofi-aventis Group.